360° SearchNetwork Hot Spots Trends Time Series

Advanced Search Options >>

Linaclotide

Type: Keyphrase

Name: Linaclotide

First reported Jun 17 2013 - Updated Jun 17 2013 - 1 reports

NHS

SMC approves linaclotide but rejects ivacaftor again

The Scottish Medicines Consortium has approved linaclotide for restricted NHS use in Scotland, but rejected ivacaftor and fluocinolone acetonide intravitreal implants.The SMC’s June assessments mean patients with irritable bowel syndrome can now be offered ... [Published PJ Online - Jun 17 2013]

Entities: Linaclotide, Metformin, NHS

First reported Jun 13 2013 - Updated Jun 14 2013 - 4 reports

IBS-C Drug Constella Launched in Europe

Constella® (linaclotide), the first approved prescription therapy in a new class of treatments for adults with IBS-C, is now available in Europe • Constella®, the first and only medicine approved by the European... ... [Published Drugs.com - Jun 14 2013]

Entities: Constella, Drugs, Linaclotide

First reported May 28 2013 - Updated May 28 2013 - 1 reports

Ironwood Pharmaceuticals Prices Public Offering of Common St. . .

Ironwood Pharmaceuticals Prices Public Offering of Common Stock [Health & Beauty Close - Up]ProQuest Information & LearningIronwood Pharmaceuticals, Inc. has announced the pricing of an underwritten public offering of 10,500,000 shares of its Class A ... [Published Equities.com - May 28 2013]

Entities: Ironwood Pharmaceuticals Inc, Linaclotide, Underwriter, Stocks, Common Shares

First reported May 25 2013 - Updated May 25 2013 - 1 reports

New treatment for IBS

Linaclotide (Constella) is now available for the symptomatic treatment of moderate to severe irritable bowel syndrome with constipation (IBS-C) in adults.Linaclotide is a first in class Guanylate Cyclase-C agonist (GCCA) that has been shown in clinical ... [Published Geriatric Medicine - May 25 2013]

Entities: IBS, Linaclotide, Constipation

First reported May 24 2013 - Updated May 24 2013 - 1 reports

Ironwood Pharmaceuticals Inc

Ironwood Pharmaceuticals Sets Price for Public Offering of Common Stock

Ironwood Pharmaceuticals, Inc. announced the pricing of an underwritten public offering of 10,500,000 shares of its Class A common stock at a price of $13.00 per share to the public. According to a release, all of the shares are being offered by Ironwood. ... [Published Individual.com - May 24 2013]

Entities: Ironwood Pharmaceuticals Inc, Common Shares, Linaclotide

First reported May 23 2013 - Updated May 23 2013 - 2 reports

Ironwood Pharmaceuticals to raise $136M in stock offering

PrintEmail Comments (0)Ironwood Pharmaceuticals Inc. will close its public offering of 10.5 million shares of stock worth nearly $136.5 million tomorrow.The Cambridge-based company said the funds will support the commercial launch of its irritable bowel ... [Published Boston Herald - May 23 2013]

Entities: Ironwood Pharmaceuticals Inc, Linaclotide, Irritable Bowel Syndrome, Stocks, Constipation

First reported May 23 2013 - Updated May 23 2013 - 1 reports

Ironwood Pharmaceuticals, Inc.: New Ironwood Pharmaceuticals, Inc. company profile published

Ironwood Pharmaceuticals, Inc. (Ironwood), formerly Microbia, Inc., is a pharmaceutical company. It develops and commercializes medicines for the treatment of chronic diseases. The company's lead product candidate, Linaclotide, is in Phase III clinical ... [Published TransWorldNews - May 23 2013]

Entities: Ironwood Pharmaceuticals Inc, Linaclotide, Constipation, Microbia Inc, Corporate Strategy

First reported May 22 2013 - Updated May 23 2013 - 2 reports

Novel IBS drug Constella hits UK shores

A first-in-class treatment for irritable bowel syndrome (IBS) has been launched in the UK this week, offering patients a new option that, for the first time, addresses a variety of symptoms caused by the condition.Almirall’s Constella (linaclotide) is ... [Published Pharma Times - May 23 2013]

Entities: Constella, IBS, Linaclotide, Drugs, Constipation

First reported May 21 2013 - Updated May 22 2013 - 2 reports

Ironwood Pharmaceuticals prices $136.5 million public offering of common stock

:Ironwood Pharmaceuticals, Inc., a US-based pharmaceuticals company, has priced an underwritten public offering of 10.5 million shares of its Class A common stock at a price of $13 per share to raise gross proceeds of $136.5 million.Ironwood has granted ... [Published Individual.com - May 22 2013]

Entities: Ironwood Pharmaceuticals Inc, Common Shares, Linaclotide, Underwriter, Stocks

First reported May 22 2013 - Updated May 22 2013 - 1 reports

Ironwood, NPS Pharma Tap Wall Street To Roll Out Lead Drugs

Ironwood Pharmaceuticals and NPS Pharmaceuticals have plenty in common: both won FDA approval of their first drugs in 2012, and both are trying to prove to investors that they can successfully sell them. And now, both have sought out Wall Street to help ... [Published Xconomy - May 22 2013]

Entities: NPS Pharmaceuticals Inc, Ironwood Pharmaceuticals Inc, Teduglutide, Drugs, Linaclotide

First reported May 20 2013 - Updated May 20 2013 - 1 reports

Ironwood Pharm (IRWD) Announces 10.5M Common Offering

Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) announced that it has commenced an underwritten public offering of 10,500,000 shares of its Class A common stock. All of the shares are being offered by Ironwood. The Company will grant the underwriters a ... [Published Street Insider - May 20 2013]

Entities: Linaclotide, Ironwood Pharmaceuticals Inc, Stocks

First reported May 20 2013 - Updated May 20 2013 - 3 reports

Ironwood Pharmaceuticals Announces 10.5M Share Proposed Publ. . .

Ironwood Pharmaceuticals Announces 10.5M Share Proposed Public Offering of Common StockEddie StaleyBenzingaIronwood Pharmaceuticals (NASDAQ: IRWD) today announced that it has commenced an underwritten public offering of 10,500,000 shares of its Class ... [Published Equities.com - May 20 2013]

Entities: Ironwood Pharmaceuticals Inc, Linaclotide, US Securities and Exchange Commission, PRELIMINARY PROSPECTUS, Supplement

Quotes

"The availability of linaclotide is excellent news for the one-third of adult IBS patients that have constipation. The symptoms associated with the condition can negatively impact the lives of patients. A targeted prescription treatment specifically for IBS-C is extremely welcome - for both appropriate patients and physicians alike who can now better manage this unpleasant, chronic condition" , said Professor Eamonn Quigley, Gastroenterologist

Almirall IBS Drug Launched in Europe [Published Pharma Live - Jun 13 2013]

According to market analyst Decision Resources, linaclotide, an investigational guanylate cyclase-C receptor, will be leading the market by 2020. "Owing to its superb efficacy, safety profile and anticipated launch in all major markets, linaclotide will achieve blockbuster sales by 2018" the group recently said

Novel IBS drug Constella hits UK shores [Published Pharma Times - May 23 2013]

...a sizeable burden on the NHS and the patient," Sarah Cripps, gastroenterology pharmacist at Oxford University Hospitals NHS Trust, told PJ Online. "However, although there is evidence of superiority over placebo, there have been no head-to-head trials and therefore no evidence of efficacy compared to current treatments."

Linaclotide launched for IBS with constipation [Published PJ Online - May 22 2013]

...symptoms very uncomfortable, for which today there are very few treatments available," said Bertil Lindmark, chief scientific officer of Almirall. "With linaclotide, physicians will have one of the first treatments designed specifically for this disease, with proven efficacy and tolerability over time. In Almirall, we are very pleased with this first treatment for IBS-C whose CHMP recommends approval and trust benefits linaclotide may bring. "

CHMP recommends approval of linaclotide for treatment of irritable bowel syndrome with constipation [Published PharmaBiz - Sep 25 2012]

More Content

sort by: Date \| Relevance
SMC approves linaclotide but rejects ivacaftor ... [Published PJ Online - Jun 17 2013]
IBS-C Drug Constella Launched in Europe [Published Drugs.com - Jun 14 2013]
Constella® (linaclotide), le premier médicament... [Published PR Newswire: Policy & Public Interest - Jun 13 2013]
Constella® (linaclotide), il primo farmaco pres... [Published PR Newswire: Policy & Public Interest - Jun 13 2013]
Almirall IBS Drug Launched in Europe [Published Drugs.com - Jun 13 2013]
Almirall IBS Drug Launched in Europe [Published Pharma Live - Jun 13 2013]
Almirall IBS Drug Launched in Europe [Published Big News Network - Jun 13 2013]
SMC 'no' for Alimera's Iluvien but Almirall dru... [Published Pharma Times - Jun 13 2013]
Seven Biotech Options That Buck Tradition: Chri... [Published Trefis - Jun 11 2013]
Seven Biotech Options that Buck Tradition: Chri... [Published InvestorIdeas.com - Jun 06 2013]
Activation of Guanylate Cyclase-C Attenuates St... [Published Journal of Neuroscience - Jun 05 2013]
Financings of the Fortnight Battles the Bull Run [Published The IN VIVO Blog - May 31 2013]
Opinion/decision on a Paediatric Investigation ... [Published Opinion/decision on a Paediatric Investigation ... - May 31 2013]
Glycopyronnium bromide gets green light for COP... [Published PJ Online - May 30 2013]
Ironwood Pharmaceuticals Prices Public Offering... [Published Equities.com - May 28 2013]
New treatment for IBS [Published Geriatric Medicine - May 25 2013]
East Coast Life Sciences Roundup: Regeneron, Ac... [Published Xconomy - May 24 2013]
Ironwood Pharmaceuticals Sets Price for Public ... [Published Individual.com - May 24 2013]
FOREST LABORATORIES INC - 10-K - Management's D... [Published Pharmacy Choice - May 24 2013]
Ironwood Pharmaceuticals to raise $136M in stoc... [Published Boston Herald - May 23 2013]
Ironwood to raise $136M to support launch of IB... [Published New York Business Journal - May 23 2013]
Ironwood Pharma Prices Stock Offering Zacks [Published Yahoo! Finance - May 23 2013]
Ironwood Pharmaceuticals, Inc.: New Ironwood Ph... [Published TransWorldNews - May 23 2013]
Novel IBS drug Constella hits UK shores [Published Pharma Times - May 23 2013]
Ironwood Pharmaceuticals prices $136.5 million ... [Published Individual.com - May 22 2013]
Ironwood, NPS Pharma Tap Wall Street To Roll Ou... [Published Xconomy - May 22 2013]
Linaclotide launched for IBS with constipation [Published PJ Online - May 22 2013]
Ironwood Pharma Prices $136.5 Mln Stock Offering [Published RTTNews.com - May 22 2013]
Ironwood Pharmaceuticals Prices Public Offering... [Published Yahoo! Finance - May 21 2013]
Synergy Is A Straightforward Opportunity: Trial... [Published Seeking Alpha - May 21 2013]

Blogs

sort by: Date \| Relevance
Financings of the Fortnight Battles the Bull Run [Published The IN VIVO Blog - May 31 2013] Since when did biotech’s epicenter move to Pamplona? The bull run has lasted quite a while now, after having gotten an extra goose, if you don’t mind mixing barnyard metaphors, around the time hepatitis C treatment developer Pharmasset became the $11 ...
Opinion/decision on a Paediatric Investigation ... [Published Opinion/decision on a Paediatric Investigation ... - May 31 2013]
Human medicines European Public Assessment Repo... [Published Pending EC decisions and European Public Assess ... - Mar 25 2013]

Press Releases

sort by: Date \| Relevance
Constella® (linaclotide), le premier médicament... [Published PR Newswire: Policy & Public Interest - Jun 13 2013]
Constella® (linaclotide), il primo farmaco pres... [Published PR Newswire: Policy & Public Interest - Jun 13 2013]
Ironwood and Forest to Present Linaclotide Data... [Published Business Wire Health News - May 14 2013]
Ironwood Completes $175 Million Debt Offering [Published EON Health & Medicine - Jan 04 2013]
Ironwood Completes $175 Million Debt Offering [Published Business Wire Professional Services News - Jan 04 2013]